Sphere Medical Holding (LSE:SPHR) ROCE % : -67.29% (As of Dec. 2016)

View and export this data going back to 2011. Start your Free Trial

What is Sphere Medical Holding ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Sphere Medical Holding's annualized ROCE % for the quarter that ended in Dec. 2016 was -67.29%.

Sphere Medical Holding ROCE % Historical Data

The historical data trend for Sphere Medical Holding's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sphere Medical Holding ROCE % Chart

Sphere Medical Holding Annual Data

Trend

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

ROCE %

Get a 7-Day Free Trial

-93.91

-81.27

-95.15

-86.00

-61.12

Sphere Medical Holding Semi-Annual Data
	Dec11	Jun12	Dec12	Jun13	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16
ROCE %	Get a 7-Day Free Trial						-121.05	-86.51	-45.46	-54.91	-67.29

Sphere Medical Holding ROCE % Calculation

Sphere Medical Holding's annualized ROCE % for the fiscal year that ended in Dec. 2016 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2016 )		(A: Dec. 2015 )		(A: Dec. 2016 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2016 )		(A: Dec. 2015 )		(A: Dec. 2016 )
	=	-5.141	/	( ( (11.538 - 0.925)	+	(6.966 - 0.757) )	/ 2 )
	=	-5.141	/	( (10.613	+	6.209)	/ 2 )
	=	-5.141	/	8.411
	=	-61.12 %

Sphere Medical Holding's ROCE % of for the quarter that ended in Dec. 2016 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2016 )		(Q: Jun. 2016 )		(Q: Dec. 2016 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2016 )		(Q: Jun. 2016 )		(Q: Dec. 2016 )
	=	-4.996	/	( ( (9.464 - 0.823)	+	(6.966 - 0.757) )	/ 2 )
	=	-4.996	/	( ( 8.641	+	6.209 )	/ 2 )
	=	-4.996	/	7.425
	=	-67.29 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2016) EBIT data.

Sphere Medical Holding (LSE:SPHR) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Sphere Medical Holding ROCE % Related Terms

Thank you for viewing the detailed overview of Sphere Medical Holding's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Sphere Medical Holding (LSE:SPHR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sphere Medical Holding PLC (LSE:SPHR) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Harston Mill, Harston, Cambridge, GBR, CB22 7GG

Website

http://www.spheremedical.com

Sphere Medical Holding Ltd is a UK-based company which is engaged in research and development, manufacturing and sale of medical monitoring and diagnostic equipment within the medical device area. It focuses on developing the Proxima platform for measuring blood gases, electrolytes and metabolites. Proxima is an in-line patient dedicated arterial blood analyser which supports frequent measurements at critical times. It markets its product (Proxima) to critical care market which includes ICU (Intensive Care Unit) and OR (Operating Room). The company's products are used in medical applications, enabling faster clinical decision-making and improved patient outcomes. It operates is business in single reporting segment of Medical devices. Most of the company's revenue comes from Europe.